How Biological E plans to take on Serum Institute in COVID-19 vaccine production
The acquisition of Akorn India helped Biological E create a potential overall manufacturing capacity of over 1 billion doses per annum.
Source: msn.com
Dev Mantena News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Dev Mantena. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Dev Mantena Today - Breaking & Trending Today
Biological E -- India's next Serum, Bharat Biotech of COVID-19 vaccine
Biological E -- India's next Serum, Bharat Biotech of COVID-19 vaccine The acquisition of Akorn India helped Biological E create a potential overall manufacturing capacity of over 1 billion doses per annum. PB Jayakumar | June 2, 2021 | Updated 23:07 IST Providence will provide necessary technology transfer for Biological E to manufacture mRNA vaccines in India. The oldest Indian private vaccine maker, Hyderabad-based Biological E Limited, is emerging as a domestic powerhouse of COVID-19 vaccine manufacturing following its latest deal with Canada-based biotech company Providence Therapeutics...
Source: businesstoday.in
India's Biological E. to start vaccine late-stage trials in April: Executive
India's Biological E. to start vaccine late-stage trials in April: Executive SECTIONS Last Updated: Dec 18, 2020, 05:54 PM IST Share Synopsis The privately held company said in November it had started early-stage and mid-stage human trials of its vaccine candidate, being developed in collaboration with Baylor College of Medicine in Houston and U.S.-based Dynavax Technologies Corp, and expects results by February. Agencies Representative Image BENGALURU: India's Biological E. Ltd plans to start large late-stage trials of its potential COVID-19 vaccine candidate in April next year, according to...
Source: indiatimes.com